Amygdala Neuroscience
Palo Alto
About Amygdala Neuroscience
Amygdala Neurosciences is developing ANS-6637 a new chemical entity with a novel MOA for treating substance use disorder. Based on a mechanism of action in the brain (published in Nature Medicine) that prevents pathophysiologic dopamine surge without changes to basal dopamine, ANS-6637 has the potential to prevent drug seeking behavior, craving and relapse. In pre-clinical studies, ALDH2 inhibition reduced self-administration, cue- and drug-primed relapse in nicotine, alcohol, cocaine, heroin, methamphetamine and binge eating models and also demonstrated anxiolytic properties in models of stress. ANS-6637 has completed extensive Phase 1 studies and is ready for Phase 2 efficacy studies. Their initial development focus is for smoking cessation with parallel development efforts for cocaine, opioid and alcohol use disorders.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $10K – $50K
- Total funding: $8.9M
- Last round: Grant (May 2024)
- Website: amygns.com
- Phone: [email protected]
Industries & Categories
Addiction Treatment, Biotechnology, Health Care, Neuroscience, Online Portals
Social Profiles
Canonical: https://fsome.com/organization/amygdala-neuroscience-95877 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.